1st Jun 2015 06:59
LONDON (Alliance News) - Hutchison China MediTech Ltd on Monday noted that AstraZeneca PLC has published preliminary data from the ongoing Phase 1b clinical trial of Hutchison MediPharma Ltd's c-Met inhibitor savolitinib combined with AstraZeneca's drug candidate AZD9291 in non-small cell lung cancer.
The preliminary data showed the 600mg combination dose was well tolerated by patients in the trial, with six partial responses from the 11 evaluable patients to date.
"Savolitinib is a highly selective c-Met inhibitor designed to eliminate the toxicities experienced by the first wave of c-Met inhibitors in their early development. We are now very pleased to see encouraging early efficacy data emerge in non-small cell lung cancer to add to the efficacy already reported in papillary renal cell carcinoma and colorectal cancer," said Hutchison China MediTech Chief Executive Christian Hogg.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
AstrazenecaHutchmed